<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03391414</url>
  </required_header>
  <id_info>
    <org_study_id>PRO09120363</org_study_id>
    <nct_id>NCT03391414</nct_id>
  </id_info>
  <brief_title>Effects of Inhaled Bicarbonate on Airway pH in Cystic Fibrosis</brief_title>
  <official_title>Effects of Inhaled Bicarbonate on Airway pH in Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joseph Pilewski</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Foundation Therapeutics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the use of inhaled concentrated sodium chloride solution to an
      inhaled solution of sodium bicarbonate in an attempt to decrease the thickness and stickiness
      of the mucus in the lungs of a person with cystic fibrosis. Also, this study is also looking
      at whether or not it is possible to decrease the acidity of the airways by inhaling sodium
      bicarbonate through nebulizer treatments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will compare the use of inhaled concentrated sodium chloride solution to an
      inhaled solution of sodium bicarbonate in an attempt to decrease the thickness and stickiness
      of the mucus in the lungs of a person with cystic fibrosis. Also, this study is also looking
      at whether or not it is possible to decrease the acidity of the airways by inhaling sodium
      bicarbonate through nebulizer treatments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exhaled breath condensate pH change</measure>
    <time_frame>two time points (baseline and four (4) hours)</time_frame>
    <description>Change in pH after inhalation of two doses on one day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expectorated sputum change</measure>
    <time_frame>two time points (Baseline and four (4) hours)</time_frame>
    <description>Change in sputum wet-to-dry ratio ratio after inhalation of two doses on one day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spirometry</measure>
    <time_frame>two time points (baseline and four (4) hours)</time_frame>
    <description>FEV1 before and after inhalation of two doses on one day</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>hypertonic bicarbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects will be administered a solution of 8.4% hypertonic bicarbonate by nebulizer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hypertonic saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects will be administered a solution of 7% sodium chloride by nebulizer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hypertonic bicarbonate</intervention_name>
    <description>8.4% sodium bicarbonate inhaled</description>
    <arm_group_label>hypertonic bicarbonate</arm_group_label>
    <other_name>sodium bicarbonate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium chloride</intervention_name>
    <description>7% sodium chloride inhaled</description>
    <arm_group_label>hypertonic saline</arm_group_label>
    <other_name>hyper-sal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. FEV1 greater than 50% predicted.

          2. Ability to spontaneously expectorate sputum (with or without chest physiotherapy).

          3. Stable disease as defined by absence of exclusion criteria numbers 3-5 and clinician
             assessment.

        Exclusion Criteria:

          1. Reactive airway disease

          2. Use of inhaled hypertonic saline in the past 28 days

          3. Use of IV antibiotics in the past 4 weeks

          4. Changes in CF-related medications in the four weeks prior to study screening

          5. SpO2 &lt; 94% on room air or use of supplemental oxygen.

          6. Presence of untreated gastroesophageal reflux disease (GERD) or residual acid reflux
             symptoms in cases of treated GERD more than three times per week.

          7. Pregnant or nursing females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph M PIlewski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UPMC Fallk Clinic</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2012</study_first_submitted>
  <study_first_submitted_qc>December 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2018</study_first_posted>
  <last_update_submitted>December 28, 2017</last_update_submitted>
  <last_update_submitted_qc>December 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Joseph Pilewski</investigator_full_name>
    <investigator_title>Associate Professor of Medicine and Pediatrics</investigator_title>
  </responsible_party>
  <keyword>thick mucus</keyword>
  <keyword>obstructive lung disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

